|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Development of carbon nanofibers from aligned electrospun polyacrylonitrile nanofiber bundles and characterization of their microstructural, electrical, and mechanical properties显示文摘 | Zhengping Zhou Chuilin Lai Lifeng Zhang Yong Qian Haoqing Hou Darrell H. Reneker Hao Fong | 2009 | Polymer2009，，13： | 2 |
| 2 | High strength electrospun polymer nanofibers made from BPDA–PDA polyimide显示文摘 | Chaobo Huang Suqing Wang Hean Zhang Tingting Li Shuiliang Chen Chuilin Lai Haoqing Hou | 2005 | European Polymer Journal2005，，5： | 1 |
| 3 | Electrospun polymer nanofibres with small diameters显示文摘 | Huang Gaobo Chen Shuiliang Lai Chuilin | 2006 | Nanotechnology2006，17，： | 1 |
| 4 | High strength electrospun polymer nanofibers made from BPDA–PDA polyimide显示文摘 | Chaobo Huang Suqing Wang Hean Zhang Tingting Li Shuiliang Chen Chuilin Lai Haoqing Hou | 2005 | European Polymer Journal2005，，5： | 1 |
| 5 | 显示文摘 | Wang Chaoxia Chen Chuilin | 2006 | Applied Surface Science2006，252，4： | 1 |
| 6 | Electrospun polyimide nanofiber membranes for high flux and low fouling microfiltration applications显示文摘 | AMIT Kumar Gautama CHUILIN Laib HAO Fong | 2014 | Journal of Membrane Science2014，466，： | 1 |
| 7 | Investigation of Post-spinning Stretching Process on Morphological,Struc-tural,and Mechanical Properties of Electrospun Polyacrylonitrile Copolymer Nanofibers显示文摘 | Lai Chuilin Zhong Ganji Yue Zhongren | 2011 | Polymer2011，52，2： | 1 |
| 8 | Electro- spun polymer nanofibres with small diameters 显示文摘 | Chaobo Huang Shuiliang Chen Chuilin Lai | 2006 | Nanotech- nology2006，17，6： | 1 |
| 9 | 卡培他滨联合固定剂量的多西紫杉醇化疗复治非小细胞肺癌的Ⅰ期临床试验(英文)显示文摘Objective:Capecitabine combined with docetaxel have demonstrated antitumor synergy for non-small cell lung cancer (NSCLC). Due to absence of phase I trial in China, we conducted this study to define the maximum-tolerated dose (MTD) of capecitabine with fixed docetaxel for Chinese patients with previously treated NSCLC. Methods:Previously treated patients with NSCLC were entered into this study. Escalating doses of capecitabine with fixed docetaxel were administered in a modified Fibonacci sequence. The initial doses were capecitabine 625 mg/m2, bid, on days d5-d18, and docetaxel 30 mg/m2 on days 1 and 8, respectively. The regimen was repeated every 21 days. If no dose-limiting toxicity (DLT) was observed, the next dose level was applied. The procedures were repeated until DLT appeared. The MTD was declared to be one dose level below the level at which DLT appeared. Results: Eighteen patients received 67 cycles at capecitabine of level I (1250 mg/m2, divided into 625 mg/m2, bid) and level II (1500 mg/m2, 750 mg/m2, bid). The most common toxicities were neutropenia, hand and feet syndrome, fatigue and nausea. Eight DLTs occurred in 5 patients in the whole group, including 1 DLT in dose level I and 7 DLTs in dose level 2. Since 4 of 6 patients in level II experienced DLTs, we declared thus level I was MTD. Conclusion: MTD of our phase I trial was capecitabine of 1250 mg/m2/d combined with docetaxel of 30 mg/m2/wk. This combination regimen was well tolerated for previously treated patients with NSCLC. The efficacy of this schedule is currently being further evaluated in a prospective phase II trial. | Qiang Lin Yue'e Liu Chuilin Chang Na Wang Jingmei Fu Xiaocang Ren Xueji Chen Jing Hu Yansheng Tian Zhijun Guo Yannan Zhao | 2012 | The Chinese-German Journal of Clinical Oncology2012，11，1： | 0 |
| 10 | Apolipoprotein C1 promotes tumor progression in gastric cancer显示文摘Background:Gastric cancer(GC)is a malignancy with the worst prognosis that seriously threatens human health,especially in East Asia.Apolipoprotein C1(apoc1)belongs to the apolipoprotein family.In addition,apoc1 has been associated with various tumors.However,its role in GC remains unclear.Methods:Firstly,we quantified its expression in GC and adjacent tumor tissues,using The Cancer Genome Atlas(TCGA).Next,we assessed cell invasion and migration abilities.Finally,we revealed the role of apoc1 in the tumor microenvironment(TME),immune cell infiltration and drug sensitivity.Results:Firstly,in TCGA database,it has been shown that elevated expression of apoc1 was identified in various cancers,including GC,then we found that high expression of apoc1 was significantly correlated with poor prognosis in GC.Histologically,apoc1 expression is proportional to grade,cancer stage,and T stage.The experimental results showed that apoc1 promoted cell invasion and migration.Then GO,KEGG,and GSEA pathway analyses indicated that apoc1 may be involved in the WNT pathway and immune regulation.Furthermore,we found out the tumor-infiltrating immune cells related to apoc1 in the tumor microenvironment(TME)using TIMER.Finally,we investigated the correlation between apoc1 expression and drug sensitivity,PD-1 and CTLA-4 therapy.Conclusions:These results suggest that apoc1 participates in the evolution of GC,and may represent a potential target for detection and immunotherapy in GC. | QIOU GU TIAN ZHAN XIAO GUAN CHUILIN LAI NA LU GUOGUANG WANG LEI XU XIANG GAO JIANPING ZHANG | 2023 | Oncology Research2023，31，3： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员